Safe Bulkers, Inc. (SB) At $3.42 Forms Top; ZEALAND PHARMA A/S (ZLDPF) SI Increased By 3.82%

ZEALAND PHARMA A/S (OTCMKTS:ZLDPF) had an increase of 3.82% in short interest. ZLDPF’s SI was 78,900 shares in January as released by FINRA. Its up 3.82% from 76,000 shares previously. With 400 avg volume, 197 days are for ZEALAND PHARMA A/S (OTCMKTS:ZLDPF)’s short sellers to cover ZLDPF’s short positions. It closed at $13.75 lastly. It is down 0.00% since January 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Safe Bulkers, Inc. (SB) formed multiple top with $3.63 target or 6.00% above today’s $3.42 share price. Safe Bulkers, Inc. (SB) has $347.73 million valuation. The stock decreased 1.58% or $0.06 during the last trading session, reaching $3.42. About 48,137 shares traded. Safe Bulkers, Inc. (NYSE:SB) has risen 124.94% since January 17, 2017 and is uptrending. It has outperformed by 108.24% the S&P500.

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide medicines in Denmark. The company has market cap of $431.19 million. The firm markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes. It currently has negative earnings. The Company’s products under development include Glepaglutide, a novel GLP-2 analogue in Phase II clinical trials for the treatment of short bowel syndrome; Dasiglucagon, a ready-to-use hypo-pen in Phase II clinical trials to treat acute, severe hypoglycemia, as well as in Phase IIa clinical trials for pump diabetes management; Elsiglutide, a novel GLP-2 analogue in Phase II clinical trials to treat chemotherapy-induced diarrhea; and GLP1-GLU, a preclinical stage product for obesity/type 2 diabetes.

Among 8 analysts covering Safe Bulkers (NYSE:SB), 3 have Buy rating, 2 Sell and 3 Hold. Therefore 38% are positive. Safe Bulkers has $5.0 highest and $0.25 lowest target. $2.75’s average target is -19.59% below currents $3.42 stock price. Safe Bulkers had 22 analyst reports since October 23, 2015 according to SRatingsIntel. Jefferies maintained Safe Bulkers, Inc. (NYSE:SB) rating on Monday, July 3. Jefferies has “Hold” rating and $2.5000 target. Citigroup maintained the shares of SB in report on Thursday, November 2 with “Sell” rating. The stock of Safe Bulkers, Inc. (NYSE:SB) has “Hold” rating given on Tuesday, May 30 by Jefferies. The stock has “Hold” rating by Jefferies on Monday, December 18. On Friday, July 29 the stock rating was downgraded by Credit Suisse to “Underperform”. The firm has “Hold” rating given on Monday, October 16 by Jefferies. The rating was downgraded by Jefferies on Friday, October 23 to “Hold”. The rating was initiated by Stifel Nicolaus with “Hold” on Friday, January 20. As per Friday, January 27, the company rating was upgraded by DNB Markets. The firm earned “Buy” rating on Friday, November 17 by Maxim Group.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: